Invitae (NVTA) Receives a New Rating from a Top Analyst
In a report released yesterday, Kevin DeGeeter from Oppenheimer assigned a Hold rating to Invitae (NVTA). The company’s shares closed last Wednesday at $47.86.
According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 70.1% and a 66.5% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Ionis Pharmaceuticals, and Cellectar Biosciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Invitae with a $64.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $61.59 and a one-year low of $7.42. Currently, Invitae has an average volume of 4.09M.
Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is neutral on the stock. Last month, Robert Nussbaum, the CMO of NVTA bought 10,101 shares for a total of $100,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.